Dr. Galsky on Resistance to Checkpoint Blockade in Metastatic Bladder Cancer

Matthew Galsky, MD
Published: Tuesday, Nov 14, 2017



Matthew Galsky, MD, professor of medicine, hematology and medical oncology, Mount Sinai Hospital, discusses resistance to checkpoint blockade in metastatic bladder cancer.

There is a growing understanding about mechanisms of intrinsic and acquired resistance to checkpoint blockade in metastatic bladder cancer.

The main reason that patients don’t respond to checkpoint inhibitors is still not fully understood, says Galsky.
 


Matthew Galsky, MD, professor of medicine, hematology and medical oncology, Mount Sinai Hospital, discusses resistance to checkpoint blockade in metastatic bladder cancer.

There is a growing understanding about mechanisms of intrinsic and acquired resistance to checkpoint blockade in metastatic bladder cancer.

The main reason that patients don’t respond to checkpoint inhibitors is still not fully understood, says Galsky.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x